Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Seattle Genetics Rocketed Higher Today

By Brian Orelli, PhD - Jul 17, 2019 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales growth of the biotech's blood cancer drug Adcetris rebounded.

What happened

Seattle Genetics ( SGEN -5.00% ) is up 16% at 11:57 a.m. EDT following the release of second-quarter earnings after the closing bell yesterday; U.S. and Canadian sales of the company's blood cancer drug Adcetris came in at $159 million, up 30% year over year and 18% quarter over quarter.

A slow start to the year likely lowered investors' expectations for the most recent quarter, setting up the opportunity for the double-digit gain.

Doctor talking to a patient in front of a window.

Image source: Getty Images.

So what

Increased use of Adcetris in peripheral T-cell lymphoma and front-line Hodgkin lymphoma drove sales higher. Management has cautioned that it would take some time to unseat the decade-old chemotherapy regimens -- even though Adcetris was proven better in clinical trials -- and that theory is starting to play out.

At this point, it seems likely that Seattle Genetics will be able to hit management's 2019 Adcetris sales guidance of $610 million to $640 million. The first half of the year brought in $294 million, and even if there's no growth for the rest of the year, sales would reach the low end of guidance: $294 + $159 + $159 = $612 million.

Now what

Clearly Seattle Genetics needs to keep its foot on the gas, pushing sales of Adcetris higher. But the next growth opportunity is around the corner, with a second drug, enfortumab vedotin, currently under review at the Food and Drug Administration for the treatment of urothelial cancer.

Given the strong data and unmet need, an approval for enfortumab vedotin seems likely -- so likely that Seattle Genetics and its partner Astellas have already started preparing for the commercial launch, including hiring a sales force so they'll be trained by the time the drug is approved.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$150.74 (-5.00%) $-7.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.